Director Kester Kent awarded 83,334 options at $5.75 at Turn (TTRX)

Rhea-AI Filing Summary

Turn Therapeutics Inc. director Kester Kent Edward received a grant of stock options covering 83,334 shares of Common Stock. The options have an exercise price of $5.75 per share and expire on June 4, 2036.

The option award vests in twelve equal monthly installments on the last day of each month, beginning June 30, 2026, subject to continued employment and the terms of the company’s 2025 Omnibus Incentive Plan. Following this grant, the reporting person holds 83,334 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Kester Kent Edward

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	83,334	$0.00	--

Holdings After Transaction: Stock option (right to buy) — 83,334 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 83,334 options Exercise price: $5.75 per share Expiration date: June 4, 2036 +2 more

5 metrics

Options granted 83,334 options Stock option grant to director Kester Kent Edward

Exercise price $5.75 per share Stock option exercise price for Common Stock

Expiration date June 4, 2036 Option term end date

Post-grant option holdings 83,334 options Total options held directly after transaction

Vesting schedule 12 equal monthly installments Vesting from June 30, 2026, subject to continued employment

Key Terms

Stock option (right to buy), Grant, award, or other acquisition, exercise price, 2025 Omnibus Incentive Plan, +1 more

5 terms

Stock option (right to buy) financial

"security_title: "Stock option (right to buy)""

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

exercise price financial

"conversion_or_exercise_price: "5.7500""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2025 Omnibus Incentive Plan financial

"subject to ... the Issuer's 2025 Omnibus Incentive Plan"

An omnibus incentive plan is a company-wide program that authorizes awards of pay tied to performance and retention—such as stock options, restricted shares, cash bonuses and other rewards—here labeled for the year it was adopted (2025). Investors care because it affects how much ownership can be issued, dilutes existing shareholders, and aligns executives’ and employees’ incentives with company goals, similar to giving team members a stake in the outcome.

vesting financial

"The option will vest in twelve (12) equal monthly installments"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kester Kent Edward

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CALIFORNIA 91362

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$5.75	06/04/2026		A		83,334		(1)	06/04/2036	Common Stock	83,334	$0	83,334	D

Explanation of Responses:

1. The option will vest in twelve (12) equal monthly installments, on the last day of each calendar month, commencing on June 30, 2026, subject to the Reporting Person's continued employment and the terms and conditions of the applicable option award and the Issuer's 2025 Omnibus Incentive Plan.

	/s/ Zuraiz Chaudhary, attorney-in-fact for Kent Edward Kester	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Turn Therapeutics (TTRX) report for Kester Kent Edward?

Turn Therapeutics reported that director Kester Kent Edward received a grant of 83,334 stock options. These options relate to Common Stock, were awarded at a $5.75 exercise price, and represent a compensation-related acquisition rather than an open-market purchase or sale of shares.

What are the key terms of the 83,334 Turn Therapeutics (TTRX) stock options?

The 83,334 stock options have a $5.75 per share exercise price and expire on June 4, 2036. They are stock options to acquire Common Stock and were granted as compensation under Turn Therapeutics’ equity incentive framework for its director.

How do the new Turn Therapeutics (TTRX) options vest for Kester Kent Edward?

The options vest in twelve equal monthly installments, each on the last day of the month, starting June 30, 2026. Vesting is conditioned on Kester Kent Edward’s continued employment and compliance with the applicable option award and 2025 Omnibus Incentive Plan terms.

Under which plan were the Turn Therapeutics (TTRX) options granted?

The stock options granted to Kester Kent Edward were issued under Turn Therapeutics’ 2025 Omnibus Incentive Plan. This plan governs the terms, conditions, and vesting requirements of the award, including continued employment and other plan-specific provisions.

What is Kester Kent Edward’s option position in Turn Therapeutics (TTRX) after this grant?

After this transaction, Kester Kent Edward directly holds 83,334 stock options in Turn Therapeutics. These options are rights to buy Common Stock at $5.75 per share, subject to the specified vesting schedule and the 2036 expiration date.